NSC antagonists are disclosed as useful in the treatment of dementia in delaying the onset of dementia and in the prevention of dementia. Dementia so treated may be for example Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone a) in combination with other drugs used for treating dementia b) in combination with drugs that stabilize or increase blood plasma glucose levels or with both a) and b). Pharmaceutical compositions dosage forms and methods for using the same are disclosed which include NSC antagonists NSC antagonists combined with dementia drugs NSC antagonists combined with glucose-level stabilizing or enhancing drugs or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time. Exemplary pharmaceutical compositions include compositions including glibenclamide and memantine; glibenclamide and donepezil; tolbutamide and memantine; tolbutamide and donepezil; and these compositions further including glucagon and/or glucose.

暂无附图